
Boeing shares rose following reports that the Trump administration is including orders for Boeing planes in trade discussions, prompting Bank of America to upgrade the stock to a buy with a $260 price target. Conversely, GM and Ford shares declined after President Trump announced a potential increase in steel and aluminum tariffs to 50%. Moderna's stock increased after receiving US approval for a new, more targeted Covid vaccine, now restricted to adults over 65 and those over 12 with risk factors.
Boeing (BA) shares experienced an uptick driven by reports that the Trump administration is integrating Boeing aircraft orders into ongoing trade discussions, a development that bolstered Bank of America's confidence, leading to an upgrade of BA stock to 'buy' from 'neutral' and a revised 12-month price target of $260, approximately 25% above its current trading price and noted as the highest on Wall Street. Bank of America analyst Ronald Epstein highlighted that Boeing aircraft have become a 'favored trade mechanism' in U.S. trade negotiations, a trend expected to persist, further supported by a record order from Qatar Airways and the cessation of China's ban on Boeing plane deliveries, collectively signaling a buying opportunity. Conversely, shares of General Motors (GM) and Ford (F) declined following President Trump's announcement of a potential hike in steel and aluminum tariffs to 50% from the existing 25%, a move aimed at protecting domestic mills but one that construction companies have previously warned would elevate material costs. Meanwhile, Moderna (MRNA) shares rose after securing U.S. approval on Saturday for a new, second-generation COVID-19 vaccine specifically for adults over 65 and individuals over 12 with at least one severe disease risk factor; this approval for a narrower demographic reflects, according to the article, a trend of regulators restricting immunization access under the leadership of Health and Human Services Secretary Robert F. Kennedy Jr., a shift from the previous broader approval for its COVID shot for those 12 and older regardless of underlying health.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Overall Sentiment
mixed
Sentiment Score
0.00
Ticker Sentiment